Brain bleed drug trial halted early – what we know
NCT ID NCT05953103
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called edaravone dexborneol (Sanbexin IV) in 80 people who had a brain bleed (intracerebral hemorrhage). The goal was to see if it is safe and helps recovery when added to standard care. The trial was stopped early, so the results are limited and more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Edaravone dexborneol (Sanbexin IV)
- What this could lead to
- If successful, this could point toward a new treatment to improve recovery after a brain bleed.
- What could go wrong
- The trial was terminated early with only 80 participants, so results are limited. It is still in early testing, so safety and effectiveness are not proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBJECTS WITH CEREBRAL HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510080, China